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Introduction 
Atopy (Greek: atopia, out of place) denotes an inherited, genetic 
predisposition or familial response resulting in the elevated 
expression of immunoglobulin E (IgE) antibodies.1 It is estimated 
that some form of an atopic disease will affect one out of every 
five people during the course of their life.1-4 In Africa’s adolescent 
population, a marked rise in the symptoms of allergic rhinitis (AR), 
atopic dermatitis as well as asthma has been observed over the 
past decade.5-7 This apparent surge of allergic diseases has been 
associated with increased global urbanisation.6 In South African 
adolescents, an increase in urbanisation has seen the prevalence 
of eczema increase from 11.8% in 1995 to 19.4% in 2001.8
The risk of developing an atopic disease is largely dependent 
on both environmental and genetic aspects related to the 
individual.1,9 Individuals who are typically termed ‘atopic’ possess a 
genetic predisposition to developing allergy-related conditions.10
Allergic rhinitis 
IgE-mediated type 1 hypersensitivity reactions are the hallmark 
of allergic rhinitis (AR). This reaction is an elevated immune 
response which is triggered by the relatively minute inhalation of 
common environmental proteins such as pollen and house dust 
mites.7 Although AR is usually characterised by a nasal discharge, 
sneezing and sinal congestion, it initially presents in the form 
of asymptomatic sensitisation. This individual, with confirmed 
allergic sensitisation to one or more allergens, does not exhibit 
clinical allergy upon his/her first exposure to an allergen.11 Only 
after initial exposure to an allergen do they become sensitised 
toward it.12 After sensitisation, re-exposure will typically result in 
an exacerbation of AR. 
AR stems from a genetic predispositioning as well as early 
childhood environmental factors. Often those not exposed to 
enough bacteria at a young age will develop an atopic condition. 
Environmental and genetic factors lead to an imbalance between 
T-helper 1 (Th1) and T-helper 2 (Th2) cellular responses. This 
imbalance between Th1 and Th2 cellular responses is at the centre 
of the pathophysiology relating to allergic diseases.13 Antibiotic 
use in early infancy is proven to cause severe disturbances in 
bowel microbiota and use of antibiotics during early childhood 
developmental phases has been positively correlated with 
an increased risk toward the development of atopy.14-16 These 
findings have created a strong link between AR and the hygiene 
hypothesis.
Pathophysiology
The pathophysiology of atopic conditions is a series of complex 
interactions between an individual’s immune system and an 
allergen. Although atopic diseases such as asthma, atopic 
dermatitis and AR present very differently, they originate from 
similar immunological abnormalities. The distinguishing factor 
among these diseases is the presentation of the clinical symptoms. 
The same allergen can easily cause three different allergic 
responses for three different people. One person may suffer an 
asthma attack upon inhaling pollen. The other may have purulent 
nasal discharge, nasal congestion and watery eyes.17-19
Individuals who are genetically predisposed will have an 
imbalance between Th1 and Th2 cellular responses, with a bias 
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toward the Th2 cellular response. The cascading immune response 
usually commences with an allergen being identified by an 
antigen-presenting cell such as a dendritic cell. Th2 cells start 
to proliferate from naïve Th0 cells presented with the allergen-
specific antigen.17-21
Th2 cellular response triggers the release of pro-inflammatory 
cytokines, IL-4, IL-5 and IL-13, which have been identified as the main 
driving forces behind AR pathophysiology. The release of these 
cytokines leads to transformation of beta-cells to IgE-producing 
plasma cells and the attraction of eosinophils. IgE produced by 
plasma cells then binds to mast cells and eosinophils via the FcεRI 
receptor. This leads to the release of histamine, prostaglandins, 
leukotrienes and other cytokines. Some eosinophilic-derived 
cytokines have also been reported to cause mucosal remodelling 
in atopic rhinitis, atopic dermatitis and atopic asthma. Depending 
on the atopic disease, various other cytokines are also involved 
in the pathology of atopic diseases.17-19 These released cytokines 
and histamine then increase capillary permeability, leading to 
plasma leakage from the nasal capillaries. They also stimulate 
sero-mucous glands to produce more mucus. These two effects 
are the main cause for nasal discharge and congestion.20-22
Approach to therapy 
Three fundamental approaches in the management of AR are in 
effect, which are non-pharmacological management, standard 
pharmacotherapy and immunotherapy. Non-pharmacological 
management possesses the ability to lessen or abolish symptoms 
of AR as well as the number of pharmacological therapies required 
for symptom alleviation and management.23,24
Non-pharmacological treatment
Allergen avoidance is a practical and simplistic form of non-
pharmacological management of AR. The initial step in this 
method includes identification of suspected allergens through 
Figure 1. A graphic representation of the pathophysiological processes in AR, including the mechanism behind the different treatment options indicated 
by the transparent X, which indicates a blockage or suppression of cascading events. Allergens are inhaled. They penetrate through the epithelial layer 
and are detected by the dendritic cells. Dendritic cells activate Th2 cellular processes. IL4, -5 and -13 are released. IL-4 stimulates B-cells to transform 
into IgE producing plasma cells. IgE freely distributes through the lamina propria and primes mast cells and basophils. Primed mast cells and basophils 
degranulate upon IgE binding to an allergen and release histamine, leukotrienes, prostaglandins and various other cytokines. These cytokines then cause 
vasodilation of the nasal arteries and increased capillary permeability of the sinal capillaries. Increased permeability leads to increased plasma leakage, 
sinal oedema and a nasal discharge. These cytokines also cause sero-mucous glands to increase mucus production. Cytokines also attract various other 
pro-inflammatory immune cells. Eosinophils that are activated by IL-5 and IL-13 also release similar cytokines to basophils and mast cells.20-22
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allergy testing or through direct identification by patients. 
Following this step, patients should take active measures to avoid 
or reduce exposure to pre-identified triggers. Allergen avoidance 
should be incorporated as an essential component in the overall 
therapeutic management of patients suffering from AR.23,25
Pharmacotherapeutic considerations should examine efficacy, 
safety, cost as well as patient preference aspects of available 
therapies. Treatment is typically administered via the oral or 
intranasal routes.23,26
Pharmacological treatment
AR management strategies usually consist of local decongestants, 
antihistamines, and corticosteroids, which are primarily utilised 
as nasal decongestants to effectively reduce nasal obstruction. 
These active pharmaceutical ingredients (APIs) may be delivered 
via various administration routes (e.g. pulmonary, oral) and the 
resultant variety of dosage forms create a pool of medicinal 
options available for tailored pharmaceutical regimens. As 
stated in ARIA (Allergic Rhinitis and its Impacts on Asthma) 
guidelines, pharmacological treatment must be individualised, 
with consideration of factors such as severity of disease, safety, 
cost-effectiveness of medications, patient’s preference, likely 
adherence to recommendations, severity and control of the 
disease, and the presence of comorbidities and polypharmacy.27 
Although antihistamines and corticosteroids are the mainstay of 
treatment for AR, local and systemic adverse effects limit their 
period of use, even if only for seasonal AR.28
Locally-acting decongestants 
These agents are characterised by adrenergic medications, 
such as phenylephrine, xylometazoline and oxymetazoline, 
which produce vasoconstriction through the stimulation of α1-
adrenergic receptors. The resultant effect is a reduction in mucosal 
oedema as well as a local dilatory effect. However, it should be 
noted that the effect of these agents is only evident for a limited 
period of time.29,30
The greatest issue associated with the use of these agents, is the 
risk of rebound nasal congestion or rebound rhinitis following 
prolonged use. These effects occur via downregulation of 
α-receptors and are characterised by nasal hyper-reactivity 
and congestion. These negative effects may become apparent 
following continuous use of these agents for periods lasting 
longer than three consecutive days. Other commonly associated 
adverse effects include nasal burning and dryness.23,31,32
Local corticosteroids
Glucocorticosteroids modify protein synthesis through regulating 
transcription and indirectly by modifying the activity or half-life of 
transcription factors and mRNA. These result in the suppression 
of Th2 cellular activity, thus various cytokines involved in the 
pathophysiology of AR are no longer synthesised and released, 
including IL-4, IL-5 and IL-13 which have been identified in the 
pathophysiology of AR.22 The following intranasal corticosteroids 
are currently available: beclomethasone, budesonide, fluticasone, 
mometasone, triamcinolone and ciclesonide. Intranasal 
administration of the newer agents, namely mometasone, 
fluticasone, and ciclesonide, will result in minimal systemic 
effects.33 The most frequent local side-effects experienced 
with the intranasal corticosteroids include dryness, stinging, 
burning, and epistaxis. Chronic use of topical corticosteroids 
may lead to atrophy of the nasal mucosa.33,34 Although the use of 
corticosteroids constitutes the most effective treatment for the 
inflammation experienced in AR, when these agents are used 
for seasonal allergic conjunctivitis, pulse dosing should rather be 
utilised, for as short a treatment duration as possible.35
Histamine-1-(H1)-antihistamines 
The overall goal of H1-antihistamine therapy is to alleviate current 
symptoms associated with allergic diseases and prevent long-term 
complications as well as symptoms.23,36 Therefore these agents 
typically see use in the treatment of allergy-related diseases, 
such as AR, allergic conjunctivitis and urticaria, where they are 
considered standard therapy.23,40 However, they do not form part 
of the mainstay of treatment in cases of severe hypersensitivity 
reactions, such as anaphylaxis and angioedema that constitute 
emergency situations. This may be attributed to antihistamines 
not relieving serious associated complications such as airway 
obstruction, shock and hypotension. The pharmacological 
mechanism by which these agents act is primarily through the 
antagonisation of H1-receptors on various target tissues. This 
resultant effect will be a lowered histamine-mediated immune 
response.23
H1-antihistamines may be sub-divided into two differing 
classes, which are the first-generation H1-antihistamines and 
the second-generation H1-antihistamines. The first-generation 
H1-antihistamines are known as the older-type agents that are 
multi-potent antagonists. These agents cross the blood-brain 
barrier to a significant degree, which precipitates their commonly 
associated sedative-like effects. In contrast, the second-generation 
H1-antihistamines possess a significantly limited ability or no 
ability to cross the blood-brain barrier and thus are noted to be 
non-sedating. These agents are also noted to be newer and are 
associated with selective H1-receptor activity. Various formulations 
of H1-antihistamines are available, such as oral, parenteral as well 
as topical preparations, which includes intranasal and ophthalmic 
agents.36-38 Examples and pharmacological characteristics of H1-
antihistamines are presented in Table I. 
• First-generation H1-antihistamines 
In consideration of the fact that these agents possess substantial 
blood-brain barrier permeability and their multi-potent 
receptor-antagonism in numerous receptor systems, it may be 
understood that their chemical structures permit non-selective 
antagonism. Their non-selective antagonism is inclusive of 
anti-muscarinic, anti-serotonergic, anti-histaminergic and α1-
adrenergic blockade effects.36,39,40 Therefore adverse effects such 
as sedation, fatigue, headache, drowsiness and xerostomia (dry 
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mouth) are prevalent in patients who utilise these agents.36,41 As 
such, Kulthanan, et al noted in their clinical practice guideline for 
the diagnosis and management of uticaria that because of the 
associated adverse effects of first-generation H1-antihistamines 
their use should be avoided in patients with contraindications, 
such as glaucoma and asthma, as well as in the elderly.37
Further, few prospective clinical pharmacology trials exist where 
these older-type H1-antihistamines were studied in special 
populations, such as paediatric and geriatric populations nor 
patients with renal or hepatic impairment. In addition, studies 
highlighting the interactions of these agents with medications, 
food and herbal agents are evident.36,42
In a randomised controlled trial, conducted by Staevska, et al, it 
was concluded that the practice of adding a first-generation H1-
antihistamine for its sedative effects at night was not supported. 
In addition, the trial also noted that their findings corresponded 
to various uticaria guidelines, which recommended only a 
second-generation H1-antihistamine without the addition of a 
first-generation agent in the treatment of uticaria.43
It should be noted that the multi-potency of their receptor-
blocking capabilities has enabled their use in several varying 
conditions and has thus broadened their indications. These 
indications include30,36,39: 
• Insomnia: Agents such as diphenhydramine and promethazine 
are noted to be effective for the short-term relief of insomnia 
through their sedative properties. 
• Allergy-related conditions: It has been established that 
chlorpheniramine exhibits fewer sedative properties and is thus 
a better agent for the management of allergy-related conditions. 
• Anti-emesis: Agents, such as cyclizine, may be useful in the 
treatment of vertigo. However, they are also indicated in the 
treatment of post-operative nausea and vomiting. 
• Second-generation H1-antihistamines 
This class of newer, non-sedating H1-antihistamines is noted 
for being long-acting in comparison to first-generation H1-
antihistamines. In addition to their lack of central nervous system 
penetration, they are devoid of any significant anti-emetic 
activity and anticholinergic-associated adverse effects.37,40 For 
the majority of these agents, their pharmacokinetics have been 
comprehensively studied in paediatric and geriatric patients. In 
addition, these effects have also been investigated in patient 
populations who suffer from renal and hepatic dysfunction.30,36,42 
However, many of these agents are metabolised by the 
cytochrome 450 enzyme during first pass hepatic metabolism 
and are therefore not recommended for patients with liver 
impairment.40 Their associated interactions with other 
medications, food and herbal products are well characterised, 
however, they are known to rarely be clinically pertinent.36 
Treatment efficiency of several second-generation H1-
antihistamines, which include desloratadine and levocetirizine, 
has been shown to be enhanced with a 4-fold dose increase 
without increasing the risk of associated adverse effects.44,43 
Synonymously, the results of a randomised controlled trial 
revealed that a 240 mg daily dose of fexofenadine reduced 
pruritus on the visual analogue scale significantly when 
compared to a 120 mg daily dose.45
Non-sedating antihistamines are proposed to be first-line 
therapy with special consideration for use in patients whose 
occupations and/or interests necessitate a lack of sedation. 
Table I. Pharmacological characteristics of typically used H1-antihistamines in allergies30,36 and Criado et al, 2010
Antihistamine Onset of action Drug interactions Associated half-life
First-generation antihistamines
Chlorpheniramine maleate (e.g. 
Allergex®; Rhineton®)
30 to 60 minutes
Alcohol, central nervous system depressants, tricyclic 
antidepressants  
Anticholinergic agents, drugs affecting CYP2D6 enzymes 
12 to 15 hours
Hydroxyzine HCl*  
(e.g. Aterax®) 2 hours








1 to 3 hours Unlikely 10 hours
Desloratadine 
(e.g. Deselex®; Dazit®, 
Pollentyme ND®)
2 hours Unlikely 27 hours
Ebastine (e.g. Kestine®) 2 hours Potential 15 to 19 hours
Fexofenadine HCl** (e.g. Telfast®; 
Tellerge®)
2 hours Unlikely 14 hours
Levocetirizine HCl (e.g. Xyzal®; 
Allerway 5; Levogex®)
Unlikely 8 hours
Loratadine (e.g. Clarityne®, 
Pollentyme®)
1 to 3 hours Unlikely 12 to 15 hours
Mizolastine (e.g. Mizollen®) 1 hour Potential 12.9 hours
*HCl – Hydrochloride. **Fexofenadine HCl has replaced terfenadine due to its severe cardiac adverse effects.
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These include patients who are heavy machinery operators, 
delivery or truck drivers and students. This is synonymous 
with the recommendation for the phasing out of sedating-
antihistamine use.37,41
Conclusion 
Various medications are available to treat AR and are generally well 
tolerated. Nonpharmacological management, such as allergen 
avoidance, should form the mainstay of therapy. Antihistamines 
should be recommended for patients presenting with mild, 
intermittent symptoms related to AR. Evidence suggests that 
second-generation antihistamines should be used in place of first-
generation antihistamines due to their more favourable adverse 
effect profiles. Pharmacists play an important role in AR treatment 
through aiding in product selection on the basis of patient-
specific symptoms and patient-individual factors, counselling 
around appropriate use of the selected product as well as patient 
referral where necessary. 
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